Approximately 40% of CRC patients exhibit KRAS mutations, including variants such as KRASG12D, KRASG12V, and KRASG13D, with the KRASG13D mutation, in particular, associated with poorer prognoses, including a higher likelihood of metastasis and reduced survival time [[8], [9], [10]]. The gene discussed is KRAS; the disease is colorectal carcinoma.